Investigational drug · Phase 3
SRG-514
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for TNBC - Triple-Negative Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SRG-514"
First trial start
2026
Dec 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SRG-514", any sponsor or status.
Conditions studied
As listed on its trial records.
- TNBC - Triple-Negative Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SRG-514" as an intervention, largest first.
- Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving SurgeryPivotal-lookingNot yet recruiting
SURGE TherapeuticsIndustry
NCT07723469 · 400 participants (planned) · Start Dec 2026 · Primary completion Oct 2034
Drug: BCS + SRG-514 · For: TNBC - Triple-Negative Breast Cancer
Sites: Rochester, Minnesota; New York, New York; Durham, North Carolina
- SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer SurgeryCompleted
SURGE TherapeuticsIndustry
NCT06300411 · 25 participants · Start Jul 29, 2024 · Primary completion Apr 8, 2026
Drug: SRG-514 · For: Breast Cancer
Sites: Savannah, Georgia; Indianapolis, Indiana; Rochester, Minnesota · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for TNBC - Triple-Negative Breast Cancer
- AVZO-021Phase 22 trials
Avenzo Therapeutics, Inc. · HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumor
- CRG-150Phase 21 trial
CoRegen, Inc. · HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer
- LP-184Phase 21 trial
Lantern Pharma Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, GBM
- TUB-030Phase 21 trial
Gilead Sciences · Advanced Solid Tumors, HNSCC, SCLC
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.